PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The bit that attracted my attention re poster 1 was a bit that was cut off the end of your copy, Burble: viz “…..complete regression of 70% of established tumours”
Also, no copy or comment re the 3rd poster on SCIB1? Or is there nothing new there?
Excellent technical summary Burble, thank you.
I asked about BionTech and the Moditope 'T' Cells back at the 2022 AGM. A that time LD was very positive that BionTech were still very much interested and those cells were being harvested at that time. So as you say its quite puzzling why we are going ahead with this research on our own.
Could it be that our price as gone to high !!
Also to add 60% of patients showing stable disease with one patient showed (past tense) a partial response. That in itself is v.interesting addition. Curious how many people have been dosed so far and how many patients this 60% stable disease refers to.
Four observations for me are as follows:
Author affiliations - none of the people listed seem to have links to BioNTech - does this mean that the 2018 collaboration to identify TCRs from moditope vaccinated people has gone quiet? Does this mean we're exploring these ourself - if so, this can be value add?
CD4+ T-cell confirmed and mapped - this demonstrates that the underlying mechanisms behind moditope are working - we are able to generate CD4+ T-cells against the moditope vaccine in patients. This evidence in addition to the resected patient information may prove beyond all doubt that moditope works and is capable of generating CD4+ responses in patients - this was something LD highlighted was high on the list that potential pharma companies would want to see. Furthermore, they stress that there is little or no-recognition to wild type - highlighting how specific this TCR is to the siPTM modified peptides.
CD8+ T-cell confirmed and mapped - this is curious to me, as LD has been keen to stress that moditope targets CD4 cells and not specifically CD8 cells. So the fact they have identified this TCR is also interesting.
Finally, from a IP perspective, I wonder what work is being done to secure this? Given that it is being presented, I'm a bit stumped as to what the IP position is on this.
isolation and characterisation of tcrs that recognise citrullinated and ****citrullinated post translationally modified peptides
s. paston1 , r. choudhury2 , s. shah2 , g. cane1 , j. chadwick1 , r. metheringham2 , f. master1 , r. herbertson3 , l. durrant1,2
1 scancell ltd, oxford, united kingdom
2 scancell ltd, nottingham, united kingdom
3 brighton and sussex university hospitals, brighton, united kingdom
under conditions of cellular stress, proteins can be post translationally modified causing them to be recognised by the immune system. one such stress induced post translational modification (siptm) modification is citrullination, the conversion of arginine residues to citrulline by peptidylarginine deiminase (pad) enzymes. we have previously shown that targeting citrullination can induce cd4 responses that provides efficient tumour therapy in vivo in a process mediated by autophagy.
we are currently running a phase 1/2, multicentre, open-label study of modi-1 in patients with breast, head and neck, ovarian, or renal cancer (the modify study) study. the moditope® vaccine incorporates two citrullinated vimentin peptides (vim28cit and vim415cit), and a citrullinated a-enolase peptide (eno241cit), each conjugated to the toll-like receptor (tlr)1/2 ligand adjuvant amplivant®. sixty percent of patients receiving modi-1 monotherapy show stable disease and one patient showed a partial response. currently we are recruiting patients receiving modi-1 in combination with checkpoint inhibitors.
eighty three percent of patients make a t cell response to eno241cit, we have isolated a tcr from one of these patients. single-cell rna- & tcrseq was performed on sorted cd4+ ifnγ+. rnaseq analysis revealed these are cytotoxic cd4 t cells, using lentivirus-tcr transduced t cells we have successfully shown that two isolated tcrs react specifically to eno241cit peptide with little or no recognition of the wild type peptide. the epitope has been mapped and the presenting hla allele identified.
another post translational modification is the carbamylation of lysine to ****citrulline. this reaction occurs when isocyanic acid reacts with the amine (nh2) groups on lysine to yield ****citrulline. the carbamylation of amine groups leads to a change in molecular charge, which in turn alters antigenic properties and can lead to the generation of unique t cell and antibody epitopes. we have successfully isolated a cd8 tcr that specifically recognises a post translationally modified peptide from aldolase. the tcr recognises a 9mer peptide that has been modified with the conversion of lysine to ****citrulline at position 7 (vlaavy-hcit-al).
using lentivirus-tcr transduced t cells we have shown that the ****citrulline peptide is recognised and not wildtype, the epitope has been mapped and the hla restriction confirmed. t-cell based immunotherapy has achieved remarkable clinical responses in cancer patients. our own data in preclinical mouse models have sh
Looking at the series of tiny trades at the start and end of the day, I can't help wondering if someone gave their lottery numbers to their stockbroker by mistake.
Thanks Bermuda. When you have had time to rake through, it would be good to know . . . anything you find. Come on you Techies !
The CIMT Annual Meeting abstracts have now been published in full - just click the '2024 Meeting Abstracts' tab towards the top of the page in the link below.
https://www.meeting.cimt.eu/call-for-abstracts
BASEL, 15 - 17 OCTOBER 2024
https://www.terrapinn.com/conference/festival-of-biologics/agenda.stm
The Festival of Biologics is your opportunity to hear from industry leaders, global regulators and world-renowned academics at the forefront of innovation. Join us for 3 days of cutting-edge insights into the latest industry developments.
October 16 th at 17:30
Reserved for Scancell
Therapeutic Vaccine Development
immunotherapy
Lindy Durrant,
Joint CEO and CSO,
Scancell Lt
ModiFY Trial, We await the following:
1 ) Mono-therapy Update
2 ) Modi1 + CPi 1st Full Data Report
3 ) Modi1 - Harvested Moditope T Cells as requested by BionTech.
4 ) Modi1 + CPi in Renal Cancer Upgraded to a 1st Line Treatment : Awaiting Approval
5 ) Modi1 + Duplet of CPi’s : Awaiting Approval to start a new cohort in Renal Carcinoma.
6 ) Neo-Adjuvant Arm where the resected tumour is analysed for the Ingress and Impact of the ModiTope generated ‘T’Cells.
7 ) Will Modi1 be linked up with a Duplet of CPi’s to target Ovarian Cancer. This would have to be fully funded with a partner as the cost of the Checkpoints would not covered by the NHS.
ModiFY is a very diverse Trial with many possible trajectories.
It is worth mentioning that "Extensive preclinical testing" of Novavax's vaccine was done at Texas Biomedical Research Institute:-
https://www.txbiomed.org/news-press/news/novavax-covid19-vaccine/
The last we heard about Covidity on 1 October'23 was that the research team at Texas Biomedical was waiting for official approval to move into primate studies, hopefully followed by FDA human clinical trials:-
https://www.ksat.com/news/local/2023/10/02/new-type-of-covid-vaccine-showing-promise-at-texas-biomed/
I'll probably emit something when it hits 50p as well to be fair.
Morning ratcliffewritter
Keeping to that theme:
lofas is a frustrated particle of energy and maybe he will also emit light when Scancell reach 50p
🤣🤣
Well said. It certainly puts lofas into a new perspective too.
Did anyone see the northern lights last night? We spent three hours gazing at the sky watching it dance in front of our eyes.
It made me realise how insignificant we are in the grand scheme of things.
There was nothing in the last presentation about
"supported by functional T cell responses to the TRP2 and gp100 peptides which can be detected in patients post vaccination"
I do think for once we may get an RNS on the morning of the presentation.
Also more tweets intresting!!
Maybe Sath also got the Tweeting Performance Manager job as well
Interesting that there has been an uptick recently in tweets from SCLP. Another one on the need for more NHS clinical cancer vaccine trials.
https://x.com/scancellpharma/status/1788929381424844835?s=46&t=A6vOxblM5AgE5_ReawinRA
Well we’re up 17% here this week 😁
Very nice up 120%
https://www.cnbc.com/amp/2024/05/10/novavax-and-sanofi-to-commercialize-covid-vaccine-develop-combo-shots.html
Save... that's the risk of investing in biotechnology companies. High risk ..High reward. As long as management spend funds carefully and have a good stragic plan...then shareholders can't blame them if things don't work out. It's the risk they take for the rewards.
Scancell do appear to lookafter the funds , have strengthened management, have an excellent strategic view... and the management don't have lifestyles at shareholders expenses. I'm confident in the management of Scancell and the risk is mine . Yes, LD had options extended but that's not a big deal in my book unless they are rolled over again. We will know Q3 Q4 the results of the SCOPE trial which will be a significant event either way..so time to get out if your not confident in either the management or the science...
Seeing "Panellists: Deborah Rathjen, Managing Director & CEO, Carina Biotech Limited" reminded me how company execs can abandon sinking ships and apparently easily get onboard elsewhere to start afresh, while shareholders are left with nothing.
Bioasis, BTI on Canadian Venture, was in the world of trying to transport therapeutic drugs over the BBB using a peptide developed from a natural human protein transporter (melanotransferrin, p97) ), which seemed to work well in the lab, but despite three changes of management, with "Dr DR" as we knew here on Stockhouse being the final attempt, they never managed to sign a partner to develop clinical trials, let alone commercialise it! "Dr DR" was living in Aus and had other roles, so that didn't help either.
See the 14-year downhill trip to oblivion here https://yhoo.it/3I5MwhI on Yahoo (Not available on the cleaner Stockcharts as they have already deleted the symbol it seems).
So, just a reminder there is more pain for shareholders than execs when things go wrong. This is not a comment on Scancell of course, just a weak coincidental connection to a biotech example in the world of startups.
Thanks Johnny and thanks to Ray also, for the reminder about Sath's other 'arm'.
Sath is a major player at Scancell now and seems to have fullest support of the CEO. IMO, he is a very considerable asset. Now for news please!
Thanks TF, never really understood about the inner workings of a companies organisation.
Sorry it is 11.40 am. This is the Agenda:-
https://drive.google.com/file/d/1-WeggpKG_BTfijvY1diwnYZa00rKpXoK/view